Aperture AC (APURU)
Aperture AC amended its memorandum and articles of association in connection with the IPO, a material corporate governance event disclosed in the Registration Statement.
View raw filing on EDGAR →Filings Radar
SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
PARKE BANCORP, INC. (PKBK)
The Board adopted a stock repurchase program authorizing repurchases of up to 5% of common stock over the next twelve months. While share repurchases are material capital allocation decisions that affect shareholder value and earnings per share, this disclosure does not fit neatly into the more specific event categories (it is not an earnings release, M&A activity, executive change, impairment, or other defined event type). The announcement is material to investors as it signals management's confidence and capital deployment strategy, but lacks a dedicated taxonomy entry.
View raw filing on EDGAR →Moleculin Biotech, Inc. (MBRX)
The disclosure announces acceptance of an abstract featuring pooled cardiac safety data for Annamycin (the company's lead drug candidate) for poster presentation at the 2026 ASCO Annual Meeting. For a clinical-stage biotech company, positive clinical data presentations at major medical conferences are material to investors assessing development progress and regulatory pathway viability. However, this does not fit neatly into the more specific event categories (it is not an earnings release, executive change, M&A activity, impairment, or litigation), so "other_material" is most appropriate.
View raw filing on EDGAR →Teucrium Commodity Trust (CORN)
The filing discloses two material definitive agreements entered into by the Fund: a Custodial Services Agreement with BitGo Bank & Trust for bitcoin safekeeping and a Master Purchase Agreement with BitGo Prime for bitcoin trading services. While these are operational agreements essential to the Fund's bitcoin holdings and trading activities, they do not constitute a traditional M&A transaction (acquisition, disposition, merger, or change of control). The agreements establish critical infrastructure for the Fund's operations but lack the transformative character typical of ma_activity events. This is best classified as other_material given the material nature of the agreements to the Fund's operations but their operational rather than transactional character.
View raw filing on EDGAR →Cayson Acquisition Corp (CAPNU)
The filing discloses that Cayson Acquisition Corp's insiders deposited a $125,000 contribution on May 21, 2026, as the third monthly installment required under a shareholder-approved extension of the business combination deadline to March 23, 2027. While this relates to a SPAC's extension mechanism and insider funding, it does not cleanly fit the standard taxonomy categories (not an M&A completion, not a shareholder vote result per se, not a covenant breach). The contribution to the trust account is material to investors assessing the company's runway and commitment to completing a business combination, but the event is primarily administrative in nature—a routine funding deposit under a previously approved extension plan.
View raw filing on EDGAR →Braemar Hotels & Resorts Inc. (BHR-PD)
The filing discloses Amendment No. 3 to the Fifth Amended and Restated Advisory Agreement between Braemar Hotels and its advisor Ashford Inc., extending the negotiation period for revised Base Fee and Incentive Fee terms through December 31, 2026. While this is a material definitive agreement amendment affecting the company's advisory fee structure, it does not fit cleanly into the more specific event categories (not M&A, not exec compensation, not a routine administrative change). The amendment's materiality lies in its potential impact on the company's operating costs and advisor relationship, warranting disclosure as a material event.
View raw filing on EDGAR →CAVCO INDUSTRIES, INC. (CVCO)
The Board approved a $150 million stock repurchase program on May 18, 2026, representing a material capital allocation decision affecting shareholder value and the company's financial flexibility.
View raw filing on EDGAR →Merck & Co., Inc. (MRK)
Merck closed a $5.5 billion underwritten public offering of debt securities across seven tranches (Floating Rate Notes, 2028, 2031, 2033, 2036, 2046, and 2056 Notes). While this is a material financing event affecting the company's capital structure and liquidity, it does not fit neatly into the specific taxonomy categories (not M&A, not a dilutive equity issuance, not a restatement or covenant breach). This is a significant debt issuance that would materially affect a reasonable investor's assessment of the registrant's financial position and leverage.
View raw filing on EDGAR →Highlands REIT, Inc.
The CEO's remarks disclose material information about the company's liquidity strategy and portfolio performance, including a decline in net asset value from $0.27 to $0.29 per share driven by Denver multifamily market softness, and acknowledgment that "uncertainty around the terms, timing, and completion risk for one material transaction in our non-core portfolio delayed our ability to deliver a liquidity event." While the disclosure centers on forward-looking plans for a potential liquidity event rather than a completed transaction or specific executive action, the material transaction delays and NAV decline would affect a reasonable investor's assessment of the REIT's near-term prospects and shareholder value realization.
View raw filing on EDGAR →iPower Inc. (IPW)
iPower Inc. implemented a 1-for-8 reverse stock split of its common stock, approved by stockholders on December 21, 2025, and effective May 22, 2026. The reverse split affects share count, per-share metrics, and trading mechanics on Nasdaq, and was announced on May 19, 2026.
View raw filing on EDGAR →Denali Therapeutics Inc. (DNLI)
The disclosure announces topline results from a Phase 2b clinical trial (LUMA study) for BIIB122 (DNL151), a Parkinson's disease candidate co-developed with Biogen. While clinical trial results are material to investors evaluating the company's pipeline and prospects, this does not fit neatly into the standard taxonomy categories (not an earnings release, M&A activity, or other enumerated event types). The Regulation FD disclosure format and emphasis on trial outcomes support classification as a material event outside the specific categories.
View raw filing on EDGAR →Sadot Group Inc. (SDOT)
Sadot Group Inc. approved and filed a 1-for-20 reverse stock split, effective May 27, 2026, explicitly intended to raise the per-share bid price above $1.00 to comply with Nasdaq Listing Rule 5550(a)(2) and address delisting risk. The amendment was disclosed via press release on May 22, 2026.
View raw filing on EDGAR →Berto Acquisition Corp. II (GUACU)
This 8-K discloses the completion of Berto Acquisition Corp. II's initial public offering (IPO) on May 18, 2026, raising $315.1 million in gross proceeds from the sale of 31.51 million units, plus a concurrent private placement of 3.5 million warrants for $3.5 million. While IPO completion is a material capital-raising event affecting the registrant's financial position and investor base, it does not fit neatly into the standard taxonomy categories (earnings_release, ma_activity, dilutive_issuance, etc.). The disclosure is material to investors as it establishes the company's public status and capital structure, but the event itself—an IPO completion—is best classified as other_material.
View raw filing on EDGAR →Golub Capital Private Credit Fund
Disclosure of fund portfolio composition, NAV per share ($4,618 million), portfolio fair value ($9,994 million), leverage ratios (1.21x debt-to-equity), and ongoing public offering activity ($3.9+ billion in Class I shares issued) as of April 30, 2026.
View raw filing on EDGAR →CNL Strategic Capital, LLC
This 8-K discloses routine monthly net asset value determinations, public offering price adjustments, and distribution declarations for CNL Strategic Capital, LLC—standard administrative disclosures for a closed-end fund. While the NAV, offering prices, and distributions are material to shareholders, they do not fit the specific event-type taxonomy (no earnings release, M&A, executive changes, impairments, covenant breaches, or other discrete triggering events). The filing is primarily informational rather than event-driven, making "other_material" the most appropriate classification.
View raw filing on EDGAR →CNL Strategic Residential Credit, Inc.
CNL Strategic Residential Credit entered into a First Amendment to its Loan and Security Agreement with Valley National Bank on May 22, 2026, expanding the existing $15 million revolving line of credit by an additional $5 million to support liquidity covenant compliance under existing repurchase agreement facilities. The amendment reflects the Company's need to enhance financial flexibility and maintain covenant compliance.
View raw filing on EDGAR →Unum Group (UNMA)
Unum Group announced a Board-authorized increase in its quarterly dividend from an unstated prior rate to 50.5 cents per share ($2.02 annualized), effective Q3 2026. While dividend increases are material to shareholders and affect total shareholder return expectations, this disclosure does not fit neatly into the more specific event categories (it is not an earnings release, executive compensation arrangement, or shareholder vote result). The event is material to a reasonable investor but is best classified as other_material given the taxonomy's specificity.
View raw filing on EDGAR →EOG RESOURCES INC (EOG)
EOG Resources' Board of Directors increased the company's share repurchase authorization from $10 billion to $20 billion effective May 20, 2026, adding $10 billion in repurchase capacity.
View raw filing on EDGAR →OLD DOMINION FREIGHT LINE, INC. (ODFL)
The company declared a quarterly cash dividend of $0.29 per share, representing a material capital allocation decision affecting shareholder returns.
View raw filing on EDGAR →SUN COMMUNITIES INC (SUI)
The filing discloses updated risk factor disclosures in connection with the proposed Park Holidays transaction and Purchase Agreement, providing supplemental disclosure of risks associated with the material M&A activity.
View raw filing on EDGAR →UNITY BANCORP INC /NJ/ (UNTY)
The registrant announced a cash dividend declaration of $0.16 per common share. While dividend declarations are routine corporate actions, they are material to shareholders as they represent a direct return of capital and signal management's confidence in cash flow. However, this does not fit neatly into the more specific event categories (it is not an earnings release, executive change, M&A activity, or financial restatement), so "other_material" is the most appropriate classification.
View raw filing on EDGAR →SR Bancorp, Inc. (SRBK)
SR Bancorp announced authorization of a third stock repurchase program for up to 10% of outstanding shares (801,320 shares). While share repurchases can signal management confidence and affect capital allocation, this disclosure does not fit neatly into the more specific event categories. The announcement is material to investors as it reflects corporate capital strategy, but lacks the specificity of a dilutive issuance or other defined event type.
View raw filing on EDGAR →AMERICAN TOWER CORP /MA/ (AMT)
The Board declared a cash distribution of $1.79 per share to shareholders, which is material to investors as it affects shareholder returns and cash flow.
View raw filing on EDGAR →COGNIZANT TECHNOLOGY SOLUTIONS CORP (CTSH)
Cognizant drew $1 billion under its revolving credit facility on May 20, 2026, creating a direct financial obligation under Item 2.03. While this is a material debt incurrence that would affect investor assessment of liquidity and leverage, it does not fit neatly into the more specific event categories (covenant_breach, going_concern, or dilutive_issuance). The filing discloses a routine credit facility draw rather than a breach, distress signal, or equity issuance, making "other_material" the most appropriate classification.
View raw filing on EDGAR →NANOVIRICIDES, INC. (NNVC)
The disclosure reveals material clinical development information about NanoViricides' drug candidates, including that NV-387 is "now entering Phase II clinical trial against Mpox in DRC" and that the company has developed an oral formulation of remdesivir encapsulated in NV-387 nanoviricide micelles with demonstrated efficacy in animal models. The company also states it has "a clinical site in DRC for treatment of Mpox patients." This represents significant clinical progress and pipeline advancement that would affect a reasonable investor's assessment of the company's development stage and commercial prospects, but does not fit neatly into the more specific event categories (not an earnings release, executive change, M&A, impairment, or litigation).
View raw filing on EDGAR →Rigetti Computing, Inc. (RGTIW)
Rigetti's wholly-owned subsidiary entered into a non-binding Letter of Intent with the U.S. Department of Commerce for a $100 million CHIPS and Science Act award over three years, contingent on negotiating definitive agreements and involving issuance of common stock to the Department at a discounted price.
View raw filing on EDGAR →COGNITION THERAPEUTICS INC (CGTX)
The disclosure announces completion of an FDA meeting regarding zervimesine for dementia with Lewy bodies patients with psychosis. This represents a material regulatory milestone for a clinical-stage biopharmaceutical company, but does not fit neatly into more specific categories (not an earnings release, M&A activity, or litigation). FDA meeting outcomes can materially affect development timelines and investor expectations for drug candidates.
View raw filing on EDGAR →KKR FS Income Trust
The Company disclosed its net asset value per Class I Share of $29.23 as of April 30, 2026 (aggregate NAV ~$1.582 billion) and reported that its ongoing private offering has raised $1.667 billion of a $5.0 billion target.
View raw filing on EDGAR →PSB Financial, Inc.
The filing discloses the closing of a subscription offering in connection with the conversion of Pioneer Federal Savings and Loan Association to a stock bank and the establishment of PSB Financial as its holding company, with the Company's common stock commencing quotation on OTCQB under symbol "PNSB" on May 22, 2026. While this represents a significant corporate restructuring and capital event, it does not fit neatly into the more specific event categories (it is not a traditional M&A activity, dilutive issuance, or earnings release), making "other_material" the most appropriate classification for this material conversion and initial public quotation event.
View raw filing on EDGAR →PERPETUA RESOURCES CORP. (PPTA)
The disclosure announces EXIM Board approval of a $2.9 billion senior secured long-term loan to support development of the Stibnite Gold Project. While this is a material financing event that would significantly affect investor assessment of the company's capital structure and project funding, it does not fit cleanly into the standard M&A taxonomy categories. The event is neither a traditional acquisition/disposition nor a debt covenant breach or going-concern disclosure, making "other_material" the most appropriate classification for this major project financing approval.
View raw filing on EDGAR →TRAVELERS COMPANIES, INC. (TRV)
The Company entered into a new $1.2 billion Five-Year Revolving Credit Agreement on May 15, 2026, replacing a prior $1.0 billion facility. While this represents a material refinancing and increase in available liquidity, it does not fit neatly into the more specific event categories (ma_activity applies to acquisitions/dispositions, not credit facility amendments; covenant_breach applies to violations, not new covenant establishment). The disclosure is material to investors as it affects the Company's financial flexibility and capital structure, but the event is best classified as other_material given the absence of a dedicated taxonomy entry for credit facility amendments or refinancings.
View raw filing on EDGAR →Adagio Medical Holdings, Inc. (ADGM)
Adagio Medical submitted a Premarket Approval (PMA) application to the FDA for its vCLAS® Ventricular Ablation System, a significant regulatory milestone for a medical device company. This event is material to investors as FDA approval is a critical path to commercialization and revenue generation, but it does not fit neatly into the more specific event categories (not an earnings release, M&A activity, impairment, litigation, or other defined types). The submission of a major regulatory application represents a material corporate development warranting disclosure under Item 8.01.
View raw filing on EDGAR →First National Master Note Trust
The filing discloses entry into material financing arrangements: an Indenture Supplement dated May 28, 2026 for issuance of "Offered Notes" and a Risk Retention Agreement among First National Bank of Omaha, First National Funding LLC, and First National Master Note Trust. While this involves debt issuance and securitization activity, the Item 8.01 classification and absence of explicit M&A language make it distinct from standard ma_activity. The disclosure of note offerings and related indenture supplements would materially affect investor assessment of the registrant's capital structure and financing activities.
View raw filing on EDGAR →BICYCLE THERAPEUTICS PLC (BCYC)
The disclosure announces initial clinical trial data (Duravelo-2) for a candidate therapeutic in metastatic urothelial cancer presented at ASCO. For a clinical-stage or development-focused biopharmaceutical company, positive or significant clinical data announcements are material to investors assessing pipeline progress and regulatory prospects. However, this does not fit neatly into the standard taxonomy categories (not earnings, M&A, impairment, litigation, etc.), warranting classification as other_material.
View raw filing on EDGAR →GCI Liberty, Inc. (GLIBK)
GCI Liberty, Inc. changed its corporate name to Liberty Capital Corporation effective May 21, 2026, through amendments to its Articles of Incorporation and Bylaws. The name change does not affect security holders' rights, trading symbols (GLIBA, GLIBB, GLIBK), or CUSIP numbers.
View raw filing on EDGAR →Black Diamond Therapeutics, Inc. (BDTX)
Black Diamond Therapeutics announced positive Phase 2 clinical trial results for silevertinib in frontline NSCLC patients with EGFR non-classical mutations, demonstrating a preliminary median progression-free survival of 15.2 months, an objective response rate of 60%, and no new safety signals.
View raw filing on EDGAR →CarParts.com, Inc. (PRTS)
CarParts.com implemented a 1-for-10 reverse stock split, effective May 25, 2026, following stockholder approval on May 11, 2026. The reverse split modifies the company's capital structure, affects share count and trading mechanics, and results in a new CUSIP number.
View raw filing on EDGAR →INSULET CORP (PODD)
Insulet Corp amended and restated its Bylaws to establish exclusive forum selection provisions for derivative actions, fiduciary duty claims, and Securities Act claims, affecting shareholders' litigation rights and corporate governance.
View raw filing on EDGAR →Beta Bionics, Inc. (BBNX)
Beta Bionics announced an updated commercialization timeline for its lead product candidate, Mint ACE insulin pump, expecting full commercialization by end of Q2 2027 subject to FDA clearance. This material product development milestone affects investor assessment of the company's near-term revenue prospects and regulatory progress.
View raw filing on EDGAR →Blackstone Real Estate Income Trust, Inc. (BSTT)
This Item 7.01 disclosure presents BREIT's Q1 2026 quarterly update, including performance metrics (+2.0% net return), portfolio composition, and strategic positioning. While it contains performance data and forward-looking commentary on real estate markets and BREIT's investment strategy, it does not constitute a formal earnings release (no complete financial statements or standardized earnings metrics), nor does it fit cleanly into other specific event categories. The disclosure is material to investors as it provides substantive updates on fund performance, portfolio allocation, and capital deployment, but the format and content are more consistent with a general investor update than a traditional earnings announcement.
View raw filing on EDGAR →Orthofix Medical Inc. (OFIX)
The FDA reclassified non-invasive bone growth stimulators from Class III to Class II, triggering CMS reimbursement changes that reduce Medicare reimbursement by approximately 10% for HCPCS codes E0747, E0748, and E0760. This regulatory action materially impacts Orthofix's financial outlook, forcing the company to lower full-year 2026 net sales guidance to $838–$848 million and adjusted EBITDA to $90–$93 million, and to withdraw its three-year financial targets. While this is a material event affecting investor assessment, it does not fit neatly into the more specific categories (it is neither a restatement, impairment, covenant breach, nor litigation), making "other_material" the most appropriate classification.
View raw filing on EDGAR →Research Alliance Corp III (RACC)
The company adopted an Amended and Restated Memorandum and Articles of Association in connection with its IPO on May 19, 2026, establishing the company's post-IPO governance structure and shareholder rights.
View raw filing on EDGAR →FLOWERS FOODS INC (FLO)
The company reset its dividend policy, reducing the annual dividend rate to $0.50 per share and declaring a quarterly dividend of $0.1250 per share, representing a significant change to shareholder return policy.
View raw filing on EDGAR →GATX CORP (GATX)
GATX Corporation amended its Five Year Credit Agreement on May 21, 2026, extending the termination date by one year to May 21, 2031 and reducing borrowing margins and facility fees. This material refinancing/restructuring of existing debt terms does not constitute an acquisition, disposition, or change of control.
View raw filing on EDGAR →Victory Capital Holdings, Inc. (VCTR)
Victory Capital entered into a Seventh Amendment to its Credit Agreement on May 18, 2026, refinancing existing term loans with repriced term loans at lower interest rates (SOFR plus 1.75% or alternate base rate plus 0.75%), materially affecting the company's debt structure and cost of capital.
View raw filing on EDGAR →Alphabet Inc. (GOOG)
Alphabet closed a ¥576.9 billion (~$3.8 billion USD equivalent) underwritten public offering of Japanese yen-denominated senior notes across seven tranches with maturities from 2029 to 2066. While this is a material debt issuance that would affect investor assessment of the company's capital structure and leverage, it does not fit cleanly into the standard M&A, dilutive equity issuance, or other specific event categories—it is a debt financing activity disclosed under Item 8.01 (Other Events).
View raw filing on EDGAR →SCHWAB CHARLES CORP (SCHW-PJ)
Charles Schwab issued $2.25 billion in aggregate principal amount of senior notes ($1 billion at 4.744% due 2030 and $1.25 billion at 5.493% due 2037) with net proceeds of approximately $2.236 million. This is a material debt issuance that does not fit the dilutive_issuance category (which applies to equity securities) and is not a covenant breach, restatement, or other more specific event type. The disclosure of a substantial debt offering is material to investors assessing the registrant's capital structure and financial position.
View raw filing on EDGAR →EagleRock Land, LLC (EROK)
EagleRock Land assumed a $263.3 million Predecessor Credit Facility (maturing July 3, 2027) and entered into a new $200 million revolving Credit Facility with JPMorgan Chase in connection with its IPO closing, materially altering the company's capital structure and leverage position.
View raw filing on EDGAR →FMC CORP (FMC)
FMC announced the pricing of a $1.2 billion offering of Senior Secured Notes due 2031. While this is a material debt issuance that would affect investor assessment of the company's capital structure and financial position, it does not fit cleanly into the taxonomy's more specific categories (ma_activity applies to acquisitions/dispositions/mergers, not debt offerings; dilutive_issuance applies to equity securities). The disclosure is material but best classified as other_material given the debt financing nature.
View raw filing on EDGAR →Olema Pharmaceuticals, Inc. (OLMA)
Olema Pharmaceuticals announced preliminary Phase 1 clinical data for OP-3136, a KAT6 inhibitor, demonstrating favorable safety, tolerability, and early efficacy signals including tumor shrinkage in 13 of 19 patients and 3 partial responses with no dose-limiting toxicities. This clinical progress is material to investors' assessment of the company's pipeline and development prospects.
View raw filing on EDGAR →